REGENXBIO announces additional positive interim phase I/IIa trial update for RGX-314
REGENXBIO announced interim data from the ongoing Phase I/IIa trial of RGX-314 for treatment of wet age-related macular degeneration. As of October 9, 2019, RGX-314 continues to be well-tolerated across all cohorts, with no drug-related serious adverse events reported. October 11, 2019